New York, November 04, 2015 -- Moody's Investors Service said the senior unsecured ratings of Teva Pharmaceutical Industries Ltd ("Teva") and its subsidiaries are likely to be downgraded by one notch, to Baa2, as a result of the debt that will be incurred to fund the proposed $40.5 billion acquisition of the generics business from Allergan plc. At this time, there is no change to Teva's Baa1 ratings, which will remain under review for downgrade until Moody's is highly certain the transaction will close as proposed. Moody's anticipates that the rating outlook will be stable.

Vollständigen Artikel bei Moodys lesen